Drug
Antiplatelets
Antiplatelets is a pharmaceutical drug with 3 clinical trials. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 2 completed trials
Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
100%(2 trials)
Phase Distribution
Ph phase_4
1
33%
Ph phase_2
1
33%
Phase Distribution
0
Early Stage
1
Mid Stage
1
Late Stage
Phase Distribution2 total trials
Phase 2Efficacy & side effects
1(50.0%)
Phase 4Post-market surveillance
1(50.0%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
100.0%
2 of 2 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Completed(2)
Other(1)
Detailed Status
Completed2
unknown1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 4
Trials by Phase
Phase 21 (50.0%)
Phase 41 (50.0%)
Trials by Status
completed267%
unknown133%
Recent Activity
0 active trials
Showing 3 of 3
completed
Non-interventional, Retrospective Cohort Study to Explore OAC Treatment in Korea
NCT03572972
completedphase_4
Evaluation of Effect of Alirocumab on Coronary Atheroma Volume in Japanese Patients Hospitalized for Acute Coronary Syndrome With Hypercholesterolemia
NCT02984982
unknownphase_2
Safety Study of Dabigatran in CADASIL
NCT01361763
Clinical Trials (3)
Showing 3 of 3 trials
NCT03572972
Non-interventional, Retrospective Cohort Study to Explore OAC Treatment in Korea
NCT02984982Phase 4
Evaluation of Effect of Alirocumab on Coronary Atheroma Volume in Japanese Patients Hospitalized for Acute Coronary Syndrome With Hypercholesterolemia
NCT01361763Phase 2
Safety Study of Dabigatran in CADASIL
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3